{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:44:26Z","timestamp":1793324666090,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1U54GM115458-01"],"award-info":[{"award-number":["1U54GM115458-01"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) remains the most aggressive primary adult brain cancer with limited therapeutic options. Our prior research demonstrated that androgen receptor antagonists (ARAs) enhance survival in GBM mouse models by preferentially suppressing glioma stem cells. This study investigates the potential of ARAs as radiosensitizers in combination with radiotherapy (RT). Combined effects of ARAs and RT were evaluated using an orthotopic GBM mouse model. RNA-Seq and TCGA analyses delineated AR-associated regulatory networks, while integrated cellular and molecular approaches utilizing human and mouse GBM cell lines, as well as in patient-derived primary high-grade glioma cultures, interrogated signaling and immune paradigms. ARA treatment induced G2\/M cell cycle arrest, apoptosis, and downregulated DNA repair genes, with AR expression correlating with the DNA repair and TGF-\u03b2 pathway. In both immortalized GBM cell lines and primary high-grade glioma cultured cells, ARAs in combination with RT showed only a modest enhancement of radiosensitivity. However, in an orthotopic GBM mouse model, ARA\u2009+\u2009RT demonstrated a strong synergy, achieving 100% long-term survival, compared to less than 50% with ARA alone and 0% with RT alone. Mechanistically, ARA modulated the TGF-\u03b2 pathway, durably switching from Smad3 linker to c-terminal phosphorylation (pSmad3C) and inhibiting the LIF\/STAT3 axis. Distinct TGF-\u03b2s ligand expression patterns were observed in ARA-treated GBM cells. A protein\u2013protein interaction noted between AR and pSmad3, which was disrupted following ARA treatment, leading to elevated protein levels and nuclear localization of pSmad3C (S423\/425), indicating normalization\/activation of the TGF-\u03b2\/pSmad3C-dependent anti-tumorigenic cascade. Comprehensive analyses in GBM cell lines and mouse model tissues demonstrated pathway reprogramming characterized by elevated TGF-\u03b22 and increased pSmad3C. Rescue experiments using a TGF\u03b2RII degrader with ARA abolished pSmad3C phosphorylation, confirming the functional significance of TGF\u03b2RII\/pSmad3C axis. Tissue analysis revealed immune activation in the tumor microenvironment, while peripheral blood and spleen showed systemic immune responses following ARA\u2009+\u2009RT. Our study provides novel insights into how ARAs enhance RT efficacy through immunomodulation involving TGF-\u03b2\/pSmad3C cascade, offering therapeutic implications in GBM.<\/jats:p>","DOI":"10.1038\/s41420-026-03259-9","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:54:20Z","timestamp":1784987660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting androgen receptor as a novel radiosensitizing therapy to improve long-term survival and anti-tumor immunity in glioblastoma via TGF-\u03b2\/Smad3 Axis reprogramming"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3185-4175","authenticated-orcid":false,"given":"Jyoti B.","family":"Kaushal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubayat","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-606X","authenticated-orcid":false,"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3553-1007","authenticated-orcid":false,"given":"Tom K.","family":"Hei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony J. C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuguo","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele R.","family":"Aizenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0463-5260","authenticated-orcid":false,"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"3259_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"3259_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997\u20131003.","journal-title":"N Engl J Med"},{"key":"3259_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JCO.2004.08.110","volume":"22","author":"JN Rich","year":"2004","unstructured":"Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:133\u201342.","journal-title":"J Clin Oncol"},{"key":"3259_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","volume":"27","author":"MJ van den Bent","year":"2009","unstructured":"van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27:1268\u201374.","journal-title":"J Clin Oncol"},{"key":"3259_CR5","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","volume":"23","author":"E Galanis","year":"2005","unstructured":"Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23:5294\u2013304.","journal-title":"J Clin Oncol"},{"key":"3259_CR6","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1100\u20138.","journal-title":"Lancet Oncol"},{"key":"3259_CR7","doi-asserted-by":"publisher","first-page":"91779","DOI":"10.18632\/oncotarget.21586","volume":"8","author":"AC Filley","year":"2017","unstructured":"Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget. 2017;8:91779\u201394.","journal-title":"Oncotarget"},{"key":"3259_CR8","doi-asserted-by":"publisher","first-page":"13-3","DOI":"10.1016\/S1470-2045(17)30517-X","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:13-3\u201385.","journal-title":"Lancet Oncol"},{"key":"3259_CR9","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1158\/1535-7163.MCT-20-0095","volume":"19","author":"CK Werner","year":"2020","unstructured":"Werner CK, Nna UJ, Sun H, Wilder-Romans K, Dresser J, Kothari AU, et al. Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. Mol Cancer Ther. 2020;19:2163\u201374.","journal-title":"Mol Cancer Ther"},{"key":"3259_CR10","doi-asserted-by":"publisher","first-page":"19980","DOI":"10.18632\/oncotarget.25007","volume":"9","author":"N Zalcman","year":"2018","unstructured":"Zalcman N, Canello T, Ovadia H, Charbit H, Zelikovitch B, Mordechai A, et al. Androgen receptor: a potential therapeutic target for glioblastoma. Oncotarget. 2018;9:19980\u201393.","journal-title":"Oncotarget"},{"key":"3259_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-72284-4","volume":"14","author":"C Zhang","year":"2024","unstructured":"Zhang C, Zhao N, Khan R, Hung MY, Zhang C, Wang S, et al. The prognostic significance of androgen receptor expression in gliomas. Sci Rep. 2024;14:22122.","journal-title":"Sci Rep"},{"key":"3259_CR12","doi-asserted-by":"publisher","first-page":"616625","DOI":"10.3389\/fonc.2021.616625","volume":"11","author":"N Zhao","year":"2021","unstructured":"Zhao N, Wang F, Ahmed S, Liu K, Zhang C, Cathcart SJ, et al. Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma. Front Oncol. 2021;11:616625.","journal-title":"Front Oncol"},{"key":"3259_CR13","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.1038\/sj.onc.1208925","volume":"24","author":"N Golestaneh","year":"2005","unstructured":"Golestaneh N, Mishra B. TGF-beta, neuronal stem cells and glioblastoma. Oncogene. 2005;24:5722\u201330.","journal-title":"Oncogene"},{"key":"3259_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/1097-0029(20010215)52:4<401::AID-JEMT1025>3.0.CO;2-C","volume":"52","author":"M Platten","year":"2001","unstructured":"Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech. 2001;52:401\u201310.","journal-title":"Microsc Res Tech"},{"key":"3259_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10369-9","volume":"10","author":"M Pascual-Garcia","year":"2019","unstructured":"Pascual-Garcia M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, et al. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 2019;10:2416.","journal-title":"Nat Commun"},{"key":"3259_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ccr.2009.02.011","volume":"15","author":"S Penuelas","year":"2009","unstructured":"Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15:315\u201327.","journal-title":"Cancer Cell"},{"key":"3259_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cells8111398","volume":"8","author":"C Piperi","year":"2019","unstructured":"Piperi C, Papavassiliou KA, Papavassiliou AG. Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment. Cells. 2019;8:11.","journal-title":"Cells"},{"key":"3259_CR18","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/stem.185","volume":"27","author":"MM Sherry","year":"2009","unstructured":"Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009;27:2383\u201392.","journal-title":"Stem Cells"},{"key":"3259_CR19","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.4161\/cc.8.9.8348","volume":"8","author":"W Gao","year":"2009","unstructured":"Gao W, Thompson L, Zhou Q, Putheti P, Fahmy TM, Strom TB, et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle. 2009;8:1444\u201350.","journal-title":"Cell Cycle"},{"key":"3259_CR20","first-page":"2866","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics (Oxford, England). 2016;32:2866\u20138.","journal-title":"Bioinformatics (Oxford, England)"},{"key":"3259_CR21","doi-asserted-by":"publisher","first-page":"e1006752","DOI":"10.1371\/journal.pcbi.1006752","volume":"15","author":"A Malyutina","year":"2019","unstructured":"Malyutina A, Majumder MM, Wang W, Pessia A, Heckman CA, Tang J. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. PLoS Comput Biol. 2019;15:e1006752.","journal-title":"PLoS Comput Biol"},{"key":"3259_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/em.1033","volume":"37","author":"A Ronen","year":"2001","unstructured":"Ronen A, Glickman BW. Human DNA repair genes. Environmental and molecular mutagenesis. 2001;37:241\u201383.","journal-title":"Environmental and molecular mutagenesis"},{"key":"3259_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1028-7","volume":"17","author":"B Li","year":"2016","unstructured":"Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17:174.","journal-title":"Genome Biol"},{"key":"3259_CR24","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic acids research. 2020;48:W509\u2013W14.","journal-title":"Nucleic acids research"},{"key":"3259_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154739","volume":"249","author":"J Song","year":"2023","unstructured":"Song J, Xiao T, Li M, Jia Q. Tumor-associated macrophages: Potential therapeutic targets and diagnostic markers in cancer. Pathol Res Pract. 2023;249:154739.","journal-title":"Pathol Res Pract"},{"key":"3259_CR26","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1021\/acsptsci.3c00371","volume":"7","author":"D L\u00e4ngle","year":"2024","unstructured":"L\u00e4ngle D, Wojtowicz-Piotrowski S, Priegann T, Keller N, Wesseler F, Reckzeh ES, et al. Expanding the Chemical Space of Transforming Growth Factor-\u03b2 (TGF\u03b2) Receptor Type II Degraders with 3, 4-Disubstituted Indole Derivatives. ACS Pharmacology & Translational Science. 2024;7:1069\u201385.","journal-title":"ACS Pharmacology & Translational Science"},{"key":"3259_CR27","doi-asserted-by":"crossref","unstructured":"Johnson AL, Khela HS, Korleski J, Sall S, Li Y, Zhou W, et al. TGFBR2High mesenchymal glioma stem cells phenocopy regulatory T cells to suppress CD4+ and CD8+ T cell function. bioRxiv 2025: 2025.2001. 2007.631757.","DOI":"10.1101\/2025.01.07.631757"},{"key":"3259_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms25010332","volume":"25","author":"N Zalcman","year":"2023","unstructured":"Zalcman N, Larush L, Ovadia H, Charbit H, Magdassi S, Lavon I. Intracranial Assessment of Androgen Receptor Antagonists in Mice Bearing Human Glioblastoma Implants. Int J Mol Sci. 2023;25:1.","journal-title":"Int J Mol Sci"},{"key":"3259_CR29","doi-asserted-by":"crossref","unstructured":"Lee J, Chung YM, Silver DJ, Hao Y, Harwood DSL, Ealy A, et al. Androgen loss accelerates brain tumour growth via HPA axis activation. Nature. 2026;653:1184\u201395.","DOI":"10.1038\/s41586-026-10451-5"},{"key":"3259_CR30","first-page":"S44","volume":"11","author":"RJ Akhurst","year":"2001","unstructured":"Akhurst RJ, Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol. 2001;11:S44\u201351.","journal-title":"Trends Cell Biol"},{"key":"3259_CR31","volume":"2012","author":"JJ Lebrun","year":"2012","unstructured":"Lebrun JJ. The Dual Role of TGFbeta in Human Cancer: From Tumor Suppression to Cancer Metastasis. ISRN Mol Biol. 2012;2012:381428.","journal-title":"ISRN Mol Biol"},{"key":"3259_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/OTT.S493643","volume":"18","author":"KA Sheikh","year":"2025","unstructured":"Sheikh KA, Amjad M, Irfan MT, Anjum S, Majeed T, Riaz MU, et al. Exploring TGF-beta Signaling in Cancer Progression: Prospects and Therapeutic Strategies. Onco Targets Ther. 2025;18:233\u201362.","journal-title":"Onco Targets Ther"},{"key":"3259_CR33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1365-2613.2010.00734.x","volume":"91","author":"SP Barry","year":"2010","unstructured":"Barry SP, Townsend PA, Knight RA, Scarabelli TM, Latchman DS, Stephanou A. STAT3 modulates the DNA damage response pathway. Int J Exp Pathol. 2010;91:506\u201314.","journal-title":"Int J Exp Pathol"},{"key":"3259_CR34","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3389\/fonc.2020.01120","volume":"10","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang X, Qiu C, Yang N. STAT3 Contributes to Radioresistance in Cancer. Front Oncol. 2020;10:1120.","journal-title":"Front Oncol"},{"key":"3259_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11060-022-04053-0","volume":"159","author":"F Wang","year":"2022","unstructured":"Wang F, Cathcart SJ, DiMaio DJ, Zhao N, Chen J, Aizenberg MR, et al. Comparison of tumor immune environment between newly diagnosed and recurrent glioblastoma including matched patients. J Neurooncol. 2022;159:163\u201375.","journal-title":"J Neurooncol"},{"key":"3259_CR36","first-page":"2112","volume":"61","author":"SA Hayes","year":"2001","unstructured":"Hayes SA, Zarnegar M, Sharma M, Yang F, Peehl DM, ten Dijke P, et al. SMAD3 represses androgen receptor-mediated transcription. Cancer Res. 2001;61:2112\u20138.","journal-title":"Cancer Res"},{"key":"3259_CR37","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1074\/jbc.M108855200","volume":"277","author":"JE Chipuk","year":"2002","unstructured":"Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ, et al. The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J Biol Chem. 2002;277:1240\u20138.","journal-title":"J Biol Chem"},{"key":"3259_CR38","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1093\/carcin\/bgr172","volume":"32","author":"K Matsuzaki","year":"2011","unstructured":"Matsuzaki K. Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis. 2011;32:1578\u201388.","journal-title":"Carcinogenesis"},{"key":"3259_CR39","first-page":"945","volume":"5","author":"J Han","year":"2015","unstructured":"Han J, Alvarez-Breckenridge CA, Wang QE, Yu J. TGF-beta signaling and its targeting for glioma treatment. Am J Cancer Res. 2015;5:945\u201355.","journal-title":"Am J Cancer Res"},{"key":"3259_CR40","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s13277-014-2709-z","volume":"36","author":"X Yu","year":"2015","unstructured":"Yu X, Jiang Y, Wei W, Cong P, Ding Y, Xiang L, et al. Androgen receptor signaling regulates growth of glioblastoma multiforme in men. Tumour Biol. 2015;36:967\u201372.","journal-title":"Tumour Biol"},{"key":"3259_CR41","doi-asserted-by":"crossref","unstructured":"Seystahl K, Papachristodoulou A, Burghardt I, Schneider H, Hasenbach K, Janicot M, et al. Biological role and therapeutic targeting of TGF-\u03b23 in glioblastoma. Mol Cancer Ther. 2017;16:1177\u201386.","DOI":"10.1158\/1535-7163.MCT-16-0465"},{"key":"3259_CR42","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.4049\/jimmunol.143.10.3222","volume":"143","author":"S Bodmer","year":"1989","unstructured":"Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol. 1989;143:3222\u20139.","journal-title":"J Immunol"},{"key":"3259_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/eji.1830180416","volume":"18","author":"C Siepl","year":"1988","unstructured":"Siepl C, Bodmer S, Frei K, MacDonald HR, De Martin R, Hofer E, et al. The glioblastoma-derived T cell suppressor factor\/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol. 1988;18:593\u2013600.","journal-title":"Eur J Immunol"},{"key":"3259_CR44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K","volume":"175","author":"MS Lucia","year":"1998","unstructured":"Lucia MS, Sporn MB, Roberts AB, Stewart LV, Danielpour D. The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells. J Cell Physiol. 1998;175:184\u201392.","journal-title":"J Cell Physiol"},{"key":"3259_CR45","first-page":"3395","volume":"42","author":"Z Liu","year":"2018","unstructured":"Liu Z, Kuang W, Zhou Q, Zhang Y. TGF-beta1 secreted by M2 phenotype macrophages enhances the stemness and migration of glioma cells via the SMAD2\/3 signalling pathway. Int J Mol Med. 2018;42:3395\u2013403.","journal-title":"Int J Mol Med"},{"key":"3259_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56796-9","volume":"16","author":"L Wieteska","year":"2025","unstructured":"Wieteska L, Taylor AB, Punch E, Coleman JA, Conway IO, Lin YF, et al. Structures of TGF-beta with betaglycan and signaling receptors reveal mechanisms of complex assembly and signaling. Nat Commun. 2025;16:1778.","journal-title":"Nat Commun"},{"key":"3259_CR47","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.annonc.2020.07.009","volume":"31","author":"D Ciardiello","year":"2020","unstructured":"Ciardiello D, Elez E, Tabernero J, Seoane J. Clinical development of therapies targeting TGFbeta: current knowledge and future perspectives. Ann Oncol. 2020;31:1336\u201349.","journal-title":"Ann Oncol"},{"key":"3259_CR48","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3389\/fimmu.2020.01184","volume":"11","author":"I Ben-Batalla","year":"2020","unstructured":"Ben-Batalla I, Vargas-Delgado ME, von Amsberg G, Janning M, Loges S. Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer. Front Immunol. 2020;11:1184.","journal-title":"Front Immunol"},{"key":"3259_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1096\/fasebj.13.1.123","volume":"13","author":"WP Benten","year":"1999","unstructured":"Benten WP, Lieberherr M, Giese G, Wrehlke C, Stamm O, Sekeris CE, et al. Functional testosterone receptors in plasma membranes of T cells. FASEB J. 1999;13:123\u201333.","journal-title":"FASEB J"},{"key":"3259_CR50","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0039-128X(02)00055-7","volume":"67","author":"WP Benten","year":"2002","unstructured":"Benten WP, Becker A, Schmitt-Wrede HP, Wunderlich F. Developmental regulation of intracellular and surface androgen receptors in T cells. Steroids. 2002;67:925\u201331.","journal-title":"Steroids"},{"key":"3259_CR51","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4049\/jimmunol.139.2.490","volume":"139","author":"WJ Kovacs","year":"1987","unstructured":"Kovacs WJ, Olsen NJ. Androgen receptors in human thymocytes. J Immunol. 1987;139:490\u20133.","journal-title":"J Immunol"},{"key":"3259_CR52","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1091\/mbc.E14-08-1323","volume":"26","author":"M Walecki","year":"2015","unstructured":"Walecki M, Eisel F, Klug J, Baal N, Paradowska-Dogan A, Wahle E, et al. Androgen receptor modulates Foxp3 expression in CD4+CD25+Foxp3+ regulatory T-cells. Mol Biol Cell. 2015;26:2845\u201357.","journal-title":"Mol Biol Cell"},{"key":"3259_CR53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2310\/JIM.0b013e318200dc98","volume":"59","author":"NJ Olsen","year":"2011","unstructured":"Olsen NJ, Kovacs WJ. Evidence that androgens modulate human thymic T cell output. J Investig Med. 2011;59:32\u201335.","journal-title":"J Investig Med"},{"key":"3259_CR54","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.4049\/jimmunol.1800352","volume":"201","author":"M Becerra-Diaz","year":"2018","unstructured":"Becerra-Diaz M, Strickland AB, Keselman A, Heller NM. Androgen and Androgen Receptor as Enhancers of M2 Macrophage Polarization in Allergic Lung Inflammation. J Immunol. 2018;201:2923\u201333.","journal-title":"J Immunol"},{"key":"3259_CR55","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/bpa.12829","volume":"30","author":"RK Kanchan","year":"2020","unstructured":"Kanchan RK, Perumal N, Atri P, Chirravuri Venkata R, Thapa I, Klinkebiel DL, et al. MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3). Brain Pathol. 2020;30:732\u201345.","journal-title":"Brain Pathol"},{"key":"3259_CR56","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953;3:285\u201390.","journal-title":"Arzneimittelforschung"},{"key":"3259_CR57","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic acids research. 2017;45:W98\u2013W102.","journal-title":"Nucleic acids research"},{"key":"3259_CR58","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/0008-5472.CAN-13-2150","volume":"74","author":"AM Sonabend","year":"2014","unstructured":"Sonabend AM, Bansal M, Guarnieri P, Lei L, Amendolara B, Soderquist C, et al. The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression. Cancer Res. 2014;74:1440\u201351.","journal-title":"Cancer Res"},{"key":"3259_CR59","doi-asserted-by":"publisher","first-page":"e20041","DOI":"10.1371\/journal.pone.0020041","volume":"6","author":"L Lei","year":"2011","unstructured":"Lei L, Sonabend AM, Guarnieri P, Soderquist C, Ludwig T, Rosenfeld S, et al. Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PLoS One. 2011;6:e20041.","journal-title":"PLoS One"},{"key":"3259_CR60","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nchembio.2131","volume":"12","author":"JA Pollock","year":"2016","unstructured":"Pollock JA, Wardell SE, Parent AA, Stagg DB, Ellison SJ, Alley HM, et al. Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. Nat Chem Biol. 2016;12:795\u2013801.","journal-title":"Nat Chem Biol"},{"key":"3259_CR61","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jneumeth.2009.02.007","volume":"179","author":"MG Uberti","year":"2009","unstructured":"Uberti MG, Boska MD, Liu Y. A semi-automatic image segmentation method for extraction of brain volume from in vivo mouse head magnetic resonance imaging using Constraint Level Sets. J Neurosci Methods. 2009;179:338\u201344.","journal-title":"J Neurosci Methods"},{"key":"3259_CR62","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41388-024-03266-z","volume":"44","author":"JB Kaushal","year":"2025","unstructured":"Kaushal JB, Raut P, Halder S, Alsafwani ZW, Parte S, Sharma G, et al. Oncogenic potential of truncated-Gli3 via the Gsk3beta\/Gli3\/AR-V7 axis in castration-resistant prostate cancer. Oncogene. 2025;44:1007\u201323.","journal-title":"Oncogene"},{"key":"3259_CR63","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fimmu.2017.00170","volume":"8","author":"G Benichou","year":"2017","unstructured":"Benichou G, Gonzalez B, Marino J, Ayasoufi K, Valujskikh A. Role of Memory T Cells in Allograft Rejection and Tolerance. Front Immunol. 2017;8:170.","journal-title":"Front Immunol"},{"key":"3259_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077322","volume":"8","author":"X Zhang","year":"2013","unstructured":"Zhang X, Chang Li X, Xiao X, Sun R, Tian Z, Wei H. CD4(+)CD62L(+) central memory T cells can be converted to Foxp3(+) T cells. PLoS One. 2013;8:e77322.","journal-title":"PLoS One"},{"key":"3259_CR65","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.freeradbiomed.2018.10.427","volume":"129","author":"JB Kaushal","year":"2018","unstructured":"Kaushal JB, Popli P, Sankhwar P, Shukla V, Dwivedi A. Sonic hedgehog protects endometrial hyperplasial cells against oxidative stress via suppressing mitochondrial fission protein dynamin-like GTPase (Drp1). Free Radic Biol Med. 2018;129:582\u201399.","journal-title":"Free Radic Biol Med"},{"key":"3259_CR66","doi-asserted-by":"crossref","unstructured":"Kaushal JB, Bhatia R, Kanchan RK, Raut P, Mallapragada S, Ly QP, et al. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh\/Gli Non-Canonical Axis of Gsk3beta. Cancers (Basel). 2021;13:3105.","DOI":"10.3390\/cancers13133105"},{"key":"3259_CR67","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jcb.22876","volume":"112","author":"C Zhang","year":"2011","unstructured":"Zhang C, Jia P, Jia Y, Li Y, Webster KA, Huang X, et al. Anoxia, acidosis, and intergenic interactions selectively regulate methionine sulfoxide reductase transcriptions in mouse embryonic stem cells. J Cell Biochem. 2011;112:98\u2013106.","journal-title":"J Cell Biochem"},{"key":"3259_CR68","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jcb.22666","volume":"111","author":"C Zhang","year":"2010","unstructured":"Zhang C, Jia P, Jia Y, Weissbach H, Webster KA, Huang X, et al. Methionine sulfoxide reductase A (MsrA) protects cultured mouse embryonic stem cells from H2O2-mediated oxidative stress. J Cell Biochem. 2010;111:94\u2013103.","journal-title":"J Cell Biochem"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03259-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03259-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03259-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:02:24Z","timestamp":1792555344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03259-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3259"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03259-9","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All mouse experiments\/procedures were duly approved and performed as per the Institutional Animal Care and Use Committee (IACUC protocol #: 16-134-01) guidelines in accordance with the National Institute of Health (NIH). The animals were maintained and operated as per IACUC standards at the University of Nebraska Medical Center (UNMC) animal facility. With informed patient consent and Institutional Review Board approval (IRB #0198-19-EP), primary high-grade glioma (HGG) cells were derived from freshly dissected tumor tissue obtained from a male patient.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors agree with the content of the manuscript and consent to publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"421"}}